KalVista Pharmaceuticals (NASDAQ:KALV) Reaches New 1-Year High – Here’s Why

KalVista Pharmaceuticals, Inc. (NASDAQ:KALV)’s share price hit a new 52-week high during trading on Wednesday . The company traded as high as $26.85 and last traded at $26.7750, with a volume of 3729340 shares traded. The stock had previously closed at $26.71.

Wall Street Analysts Forecast Growth

KALV has been the topic of a number of recent analyst reports. Leerink Partners lowered KalVista Pharmaceuticals from a “strong-buy” rating to a “hold” rating in a report on Wednesday, April 29th. JonesTrading lowered KalVista Pharmaceuticals from a “strong-buy” rating to a “hold” rating in a report on Thursday, April 30th. Weiss Ratings reiterated a “sell (d-)” rating on shares of KalVista Pharmaceuticals in a report on Tuesday, April 21st. Stifel Nicolaus lifted their price target on KalVista Pharmaceuticals from $39.00 to $42.00 and gave the stock a “buy” rating in a report on Thursday, March 26th. Finally, Needham & Company LLC lowered KalVista Pharmaceuticals from a “buy” rating to a “hold” rating in a report on Thursday, April 30th. Three equities research analysts have rated the stock with a Buy rating, five have assigned a Hold rating and one has issued a Sell rating to the stock. According to data from MarketBeat, the company presently has a consensus rating of “Hold” and an average price target of $30.60.

KalVista Pharmaceuticals Stock Performance

The company has a debt-to-equity ratio of 8.18, a quick ratio of 7.21 and a current ratio of 7.22. The company has a market capitalization of $1.37 billion, a P/E ratio of -6.76 and a beta of -0.12. The business has a 50 day moving average of $18.67 and a 200-day moving average of $15.88.

Insider Activity at KalVista Pharmaceuticals

In related news, CEO Benjamin L. Palleiko sold 9,550 shares of the business’s stock in a transaction on Friday, April 17th. The stock was sold at an average price of $20.22, for a total transaction of $193,101.00. Following the sale, the chief executive officer directly owned 462,577 shares in the company, valued at approximately $9,353,306.94. The trade was a 2.02% decrease in their position. The transaction was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Also, insider Nicole Sweeny sold 1,862 shares of the business’s stock in a transaction on Friday, April 17th. The shares were sold at an average price of $20.22, for a total value of $37,649.64. Following the sale, the insider owned 51,391 shares in the company, valued at approximately $1,039,126.02. The trade was a 3.50% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Insiders sold a total of 263,969 shares of company stock worth $4,536,178 in the last 90 days. 4.30% of the stock is owned by company insiders.

Institutional Trading of KalVista Pharmaceuticals

Hedge funds and other institutional investors have recently made changes to their positions in the stock. BNP Paribas Financial Markets raised its stake in shares of KalVista Pharmaceuticals by 47.0% during the 2nd quarter. BNP Paribas Financial Markets now owns 4,041 shares of the specialty pharmaceutical company’s stock valued at $46,000 after purchasing an additional 1,292 shares during the period. Zurcher Kantonalbank Zurich Cantonalbank bought a new stake in shares of KalVista Pharmaceuticals during the 3rd quarter valued at $55,000. Wolverine Asset Management LLC bought a new stake in shares of KalVista Pharmaceuticals during the 3rd quarter valued at $57,000. Truvestments Capital LLC raised its stake in shares of KalVista Pharmaceuticals by 253.8% during the 4th quarter. Truvestments Capital LLC now owns 4,684 shares of the specialty pharmaceutical company’s stock valued at $76,000 after purchasing an additional 3,360 shares during the period. Finally, KLP Kapitalforvaltning AS bought a new stake in shares of KalVista Pharmaceuticals during the 3rd quarter valued at $63,000.

About KalVista Pharmaceuticals

KalVista Pharmaceuticals is a clinical‐stage biotechnology company focused on the discovery and development of small‐molecule protease inhibitors for orphan and specialty disease indications. The firm’s scientific platform centers on selective inhibition of plasma kallikrein, a serine protease implicated in disorders characterized by vascular leak, edema and inflammation. KalVista’s approach leverages oral and intravitreal delivery formats to target both systemic and ophthalmic conditions.

The company’s lead programs include an oral plasma kallikrein inhibitor in clinical trials for the acute treatment of hereditary angioedema (HAE) attacks and an intravitreal kallikrein inhibitor being evaluated for diabetic macular edema.